Jae Cheol Jo
Korea University
2 Papers
Jae Cheol Jo is an academic researcher from Korea University. The author has contributed to research in topics: Bortezomib & Daratumumab. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer,Suzanne Lentzsch,Katja Weisel,Hervé Avet-Loiseau,Tomer M Mark,Ivan Spicka,Tamás Masszi,Birgitta Lauri,Mark-David Levin,Alberto Bosi,Vania Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Cindy Lee,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Emma C. Scott,Asher Chanan-Khan,Noemi Horvath,Marcelo Capra,Meral Beksac,Roberto Ovilla,Jae Cheol Jo,Ho Jin Shin,Pieter Sonneveld,David Soong,Tineke Casneuf,Christopher Chiu,Himal Amin,Ming Qi,Piruntha Thiyagarajah,A. Kate Sasser,Jordan M. Schecter,Maria-Victoria Mateos +36 more
TL;DR: Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse.
248
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Katja Weisel,Andrew Spencer,Suzanne Lentzsch,Hervé Avet-Loiseau,Tomer M Mark,Ivan Spicka,Tamás Masszi,Birgitta Lauri,Mark-David Levin,Alberto Bosi,Vania Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Markus Munder,Cindy Lee,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Asher Chanan-Khan,Noemi Horvath,Marcelo Capra,Meral Beksac,Roberto Ovilla,Jae Cheol Jo,Ho Jin Shin,Pieter Sonneveld,Tineke Casneuf,Nikki A. Deangelis,Himal Amin,Jon Ukropec,Rachel Kobos,Maria-Victoria Mateos +33 more
TL;DR: New data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status, as well as the safety profile of CASTOR.